A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Exclusion Criteria

• •1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
• •2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
• •3. Pregnant (or lactating) women;
• •4. With a graft-versus-host response, immunosuppressants are required;
• •5. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
• •6. Active infection of hepatitis B virus or hepatitis C virus;
• •7. Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids;
• •8. Previously treated with any CAR-T cell product or other genetically-modified T cell therapies;
• •9. Creatinine\>2.5mg/dl, or ALT / AST \> 3 times of normal amounts, or bilirubin\>2.0 mg/dl;
• •10. Other uncontrolled diseases that were not suitable for this trial;
• •11. Patients with HIV infection;
• •12. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.